Hostname: page-component-cd9895bd7-hc48f Total loading time: 0 Render date: 2024-12-24T13:57:53.440Z Has data issue: false hasContentIssue false
  • English
  • Français

Adaptación social y trastorno de ansiedad generalizada: un estudio a largo plazo controlado con placebo de la venlafaxina de liberación prolongada

Published online by Cambridge University Press:  12 May 2020

Patrice Boyer ,
Vincent Mahé  and
David Hackett
Patrice Boyer
Affiliation:
CNRS UMR 7593, Hôpital de la Pitié-Salpétriére, 47, Boulevard de L’Hôpital, 75651París, Francia
Vincent Mahé
Affiliation:
Servicio de Psiquiatría, Hospital General de Meaux, Francia
David Hackett
Affiliation:
Wyeth Research, París, Francia
Get access

Resumen

El objetivo de este análisis era evaluar la eficacia a corto (8 semanas) y largo plazo (24 semanas) de tres dosis fijas de venlafaxina de liberación prolongada (LP) y placebo en la adaptación social de los pacientes contrastorno de ansiedad generalizada (TAG). Analizamos los datos de 544 pacientes ambulatorios que participant en un estudio multicéntrico doble ciego de grupos paralelos controlado con placebo de 24 semanas realizado en 55 centros en cinco países. Todos los pacientes cumplían los criterios del DSM-IV para TAG y se asignaron aleatoriamente para recibir 37,5, 75 y 150 mg de venlafaxina LP o placebo emparejado administrado oralmente una vez al día. La adaptación social se midió utilizando la Escala de Adaptación Social-Autoinforme, que explora la adaptación social en las áreas laboral, social y de ocio, familia extensa, relación primaria (matrimonial), parental y unidad familiar. En la línea de base, los pacientes con TAG tenían un nivel alto de disfunción social. La venlafaxina LP mostró una mejoría relacionada con la dosis en el deterioro social durante el tratamiento a corto plazo y en el mantenimiento de esta mejoria a largo plazo. En el subgrupo con deterioro social mas importante, las tasas de remisión con el placebo en la HAM-A fueron bajas, y la magnitud de la diferencia venlafaxina-placebo en la puntuación total media de la HAM-A fue alta, alcanzando más de 7 puntos. Los beneficios del tratamiento de venlafaxina LP del TAG se extienden más alia de la mejoría de los síntomas de ansiedad, a una mejoría significativa en el deterioro del funcionamiento que se asocia con la enfer medad.

Keywords

Trastorno de ansiedad generalizadaDeterioro socialVenlafaxina
Type
Artículo original
Information
European Psychiatry (Ed. Española) , Volume 11 , Issue 8 , November 2004 , pp. 500 - 507
Copyright
Copyright © European Psychiatric Association 2000

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bibliografía

Allgulander, C, Hackett, D, Salinas, E.Venlafaxine extended ralease (ER) in the treatment of generalised anxiety disorder: twenty-fourweek placebo-controlled dose-ranging study. Br J Psychiatry 2001;179:15–22.CrossRefGoogle ScholarPubMed
American Psychiatric Association. DSM-IV: diagnostic and statistical manual of mental disorders. 4th ed. Washington (DC): American Psychiatric Association; 1994.Google Scholar
Anderson, DJ, Noyes, R Jr, Crowe, RR.A comparison of pañic disorder and generalized anxiety disorder. Am J Psychiatry 1984;141:572–5.Google ScholarPubMed
Andrews, JM, Ninan, PT, Nemeroff, CB.Venlafaxine: a novel antide-pressant that has a dual mechanism of action. Depression 1996; 4:48–56.3.0.CO;2-B>CrossRefGoogle Scholar
Barlow, DH, Blanchard, EB, Vermilyea, JA, Vermilyea, BB, DiNardo, PA.Generalized anxiety and generalized anxiety disorder: description and reconceptualisation. Am J Psychiatry 1986;143:40–44.Google Scholar
Davidson, JR, DuPont, RL, Hedges, D, Haskins, JT.Efficacy, safety, and tolerability of venlafaxine extended ralease and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry 1999;60:528–535.CrossRefGoogle ScholarPubMed
Faravelli, C, Guerrini, Degl'Innocenti B, Giardinelli, L.Epidemiology of anxiety disorders in Florence. Acta Psychiatr Scand 1989;79:30812.CrossRefGoogle ScholarPubMed
Gelenberg, AJ, Lydiard, RB, Rudolph, RL, Aguiar, L, Haskins, JT, Salinas, E.Efficacy of venlafaxine extended-ralease capsules in non-depressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial. JAMA 2000;283:3082–3088.CrossRefGoogle Scholar
Guy, W, National Institute of Mental Health (US). Psychopharmacology Research Branch. Early Clinical Drug Evaluation Program. ECDEU assessment manual for psychopharmacology. Rockville, MD: U.S. Dept. of Health, Education, and Welfare, Public Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, División of Extramural Research Programs; 1976 Revised ed.Google Scholar
Hamilton, M.The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50–55.CrossRefGoogle ScholarPubMed
Keller, M.Role of serotonin and noradrenaline in social dysfunction: a review of data on reboxetine and the Social Adaptation Self-evaluation Scale (SASS). Gen Hospital Psychiatry 2001;23:15–19.CrossRefGoogle Scholar
Kessler, RC, Frank, RG.The impact of psychiatric disorders on work loss days. Psychol Med 1997;27:861–873.CrossRefGoogle ScholarPubMed
Kessler, RC, McGonagle, KA, Zhao, S, Nelson, CB, Hughes, M, Eshleman, S, et al.Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8–19.CrossRefGoogle ScholarPubMed
Khan, A, Upton, GV, Rudolph, RL, Entsuah, R, Leventer, SM.The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. J Clin Psychopharmacol 1998;18:19–25.CrossRefGoogle ScholarPubMed
Leaf, PJ, Weissman, MM, Myers, JK, Tischler, GL, Holzer, CE. 3d Social factors related to psychiatric disorder: the Yale Epidemiologic Catchment Area study. Soc Psychiatry 1984;19:53–61.CrossRefGoogle ScholarPubMed
Luty, SE, Joyce, PR, Mulder, RT.Comparison between noradrenergic and serotonergic medications using the social adjustment scale: is drive enhancement necessary for recovery of social functioning? J Psychopharmacol 2001;15:257–264.CrossRefGoogle ScholarPubMed
Noyes, R Jr, Clarkson, C, Crowe, RR, Yates, WR, McChesney, CM.A family study of generalized anxiety disorder. Am J Psychiatry 1987;144:1019–24.Google ScholarPubMed
Pollack, MH, Zaninelli, R, Goddard, A, McCafferty, JP, Bellew, KM, Burnham, DB, et al.Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry 2001;62:350–357.CrossRefGoogle ScholarPubMed
Rickels, K.Antianxiety therapy: potential valué of long-term treatment. J Clin Psychiatry 1987;48:7–11.Google ScholarPubMed
Rickels, K, Downing, R, Schweizer, E, Hassman, H.Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry 1993;50:884–895.CrossRefGoogle ScholarPubMed
Rickels, K, Pollack, MH, Sheehan, DV, Haskins, JT.Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry 2000; 157:968–74.CrossRefGoogle ScholarPubMed
Rickels, K, Schweizer, E.The clinical course and long-term management of generalized anxiety disorder. J Clin Psychopharmacol 1990; 10:101S–10S.CrossRefGoogle ScholarPubMed
Robins, LN, Regier, DA, editors. Psychiatric disorders in America: the epidemiologic catchment area study. New York, NY: Free Press; 1991.Google Scholar
Souetre, E, Lozet, H, Cimarosti, I, Martin, P, Chignon, JM, Ades, J, et al.Cost of anxiety disorders: impact of comorbidity. J Psychosom Res 1994;38:151–160.CrossRefGoogle ScholarPubMed
Tse, WS, Bond, AJ.Difference in serotonergic and noradrenergic regulation of human social behaviours. Psychopharmacol 2002;159:216–221.CrossRefGoogle ScholarPubMed
Üstün, TB, Sartorius, N, editors. Mental illness in general health care: an international study. Chichester, NY: Wiley; 1995.Google Scholar
van Praag, HM, Asnis, GM, Kahn, RS, et al.Mopo-amines and abnormal behaviour. A multi-aminergic perspective. Br J Psychiatry 1990;157:723–734.CrossRefGoogle ScholarPubMed
Wacker, HR, Mullejans, R, Klein, KH, Battegay, R.Identification of cases of anxiety disorders and affective disorders in the community according to ICD-10 and DSM-III-R by using the Composite International Diagnostic Interview (CIDI). Int J Methods Psychiatr Res 1992;2:91–100.Google Scholar
Weissman, M, Staff, MHS.SAS-SR social adjustment scale selfreport technical manual. 1999.Google Scholar
Weissman, MM, Bothwell, S.Assessment of social adjustment by patient self-report. Arch Gen Psychiatry 1976;33:1111–1115.CrossRefGoogle ScholarPubMed
Weissman, MM, Prusoff, BA, Thompson, WD, Harding, PS, Myers, JK.Social adjustment by self-report in a community sample and in psychiatric outpatients. J Nerv Ment Dis 1978;166:317–326.CrossRefGoogle Scholar
Wittchen, HU, Zhao, S, Kessler, RC, Eaton, WW.DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:355–364.CrossRefGoogle ScholarPubMed
Yonkers, KA, Warshaw, MG, Massion, AO, Keller, MB.Phenomenology and course of generalised anxiety disorder. Br J Psychiatry 1996;168:308–313.CrossRefGoogle ScholarPubMed
Zigmond, AS, Snaith, RRThe hospital anxiety and depression scale. Acta Psychiatr Stand 1983;67:361–370.CrossRefGoogle ScholarPubMed